跳至主要内容
临床试验/NCT00595465
NCT00595465已完成3 期

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.

Valneva Austria GmbH4 个研究点 分布在 2 个国家目标入组 389 人开始时间: 2007年12月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
389
试验地点
4
主要终点
Geometric Mean Titer (GMT) for Anti-JEV Neutralizing Antibody

研究概览

简要总结

The objective is to demonstrate equivalence of three commercial IC51 batches in terms of geometric mean titers for anti-JEV neutralizing antibody

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Main Inclusion Criteria:
  • •Male and female healthy adults aged at least 18 years, with written informed consent and either no childbearing potential or negative pregnancy test

排除标准

  • •History of immunodeficiency or immunosuppressive therapy,
  • •Known Human Immunodeficiency Virus (HIV); OR
  • •Drug addiction including alcohol dependence

研究组 & 干预措施

IC51 Batch A

Active Comparator

干预措施: Japanese Encephalitis purified inactivated vaccine (Biological)

IC51 Batch B

Active Comparator

干预措施: Japanese Encephalitis purified inactivated vaccine (Biological)

IC51 Batch C

Active Comparator

干预措施: Japanese Encephalitis purified inactivated vaccine (Biological)

结局指标

主要结局

Geometric Mean Titer (GMT) for Anti-JEV Neutralizing Antibody

时间窗: Day 56

次要结局

  • Seroconversion Rate(Day 56)
  • Safety and Adverse Events(Day 56)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验